Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04606901 · ClinicalTrials.gov registry record · Phase 4
Comparison of Time to Extubation Using Sugammadex or Neostigmine
A Phase 4 study, sponsored by Temple University.
- Completed
- Registry status
- Phase 4
- Development phase
- 58
- Enrollment target
NCT04606901: Completed Phase 4 study, sponsored by Temple University.
NCT04606901 is a Phase 4 study that has completed, run by Temple University. The registered enrollment target is 58 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04606901, a Phase 4 study, has completed, sponsored by Temple University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 58 participants
- Enrollment target
Study Summary
A prospective blinded randomized clinical trial to compare time to extubation using Sugammadex versus Neostigmine/glycopyrrolate as reversal agents after use of neuromuscular blockade agents in an outpatient bronchoscopy suite.
Primary Outcome
number of minutes from reversal dose to Train of Four (TOF) \>0.9 indicating full reversal of neuromuscular blockade agent
Interventions
- DRUG sugammadex
- DRUG neostigmine/glycopyrrolate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2021-04-08 |
| Est. Completion | 2023-07-30 |
| Phase | Phase 4 |
What the finished NCT04606901 record still lists
NCT04606901 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 2 interventions - of which sugammadex is the first listed.
NCT04606901 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04606901 about?
NCT04606901 is a clinical study titled "Comparison of Time to Extubation Using Sugammadex or Neostigmine". A prospective blinded randomized clinical trial to compare time to extubation using Sugammadex versus Neostigmine/glycopyrrolate as reversal agents after use of neuromuscular blockade agents in an outpatient bronchoscopy suite.
What is the current status of trial NCT04606901?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 58 participants. The study started on 2021-04-08. Estimated completion is 2023-07-30.
What interventions are being tested in trial NCT04606901?
The interventions under investigation include: sugammadex (DRUG), neostigmine/glycopyrrolate (DRUG).
Who is sponsoring clinical trial NCT04606901?
This trial is sponsored by Temple University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04606901's enrollment target sits among peer trials
58 1205th of 2000 higher than 792 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI